{
  "profiles": [
    {
      "pi_name": "Ka Yu Tse, MBBS, MMedSc, PhD, FRCOG",
      "institution": "The University of Hong Kong",
      "nct_id": "NCT07022535",
      "trial_details": {
        "title": "Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "KELIM",
          "Carboplatin plus Paclitaxel",
          "Interval debulking surgery"
        ]
      },
      "publications": [
        "40908776",
        "40611334",
        "39776385"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Ka Yu Tse,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer\" (NCTNCT07022535) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "Phase 2 - may have preliminary outcomes",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117626"
    },
    {
      "pi_name": "Clinical Trial Management",
      "institution": "Regeneron Pharmaceuticals",
      "nct_id": "NCT04590326",
      "trial_details": {
        "title": "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",
        "phase": [
          "PHASE1",
          "PHASE2"
        ],
        "interventions": [
          "REGN5668",
          "Cemiplimab",
          "Ubamatamab",
          "Sarilumab",
          "Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]"
        ]
      },
      "publications": [],
      "kelim_fit": {
        "fit_reasons": [],
        "fit_score": 0
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Clinical,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab\" (NCTNCT04590326) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "Phase 2 - may have preliminary outcomes",
        "kelim_relevance": []
      },
      "targeted_value_props": [],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117675"
    },
    {
      "pi_name": "David Alberts, MD",
      "institution": "University of Arizona",
      "nct_id": "NCT00442598",
      "trial_details": {
        "title": "Safety and Efficacy Study of Glufosfamide in Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Glufosfamide"
        ]
      },
      "publications": [
        "38640774",
        "36608382",
        "34216135"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. David Alberts,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"Safety and Efficacy Study of Glufosfamide in Ovarian Cancer\" (NCTNCT00442598) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "Phase 2 - may have preliminary outcomes",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117702"
    },
    {
      "pi_name": "Dae-Yeon Kim",
      "institution": "Asam Medical Center",
      "nct_id": "NCT07295132",
      "trial_details": {
        "title": "RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Secondary cytoreductive surgery",
          "Platinum Based Chemotherapy"
        ]
      },
      "publications": [
        "41311345",
        "40943311",
        "40842255"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Uses platinum therapy",
          "Has relevant publications"
        ],
        "fit_score": 2
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Dae-Yeon,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)\" (NCTNCT07295132) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n- Platinum-based therapy - perfect for KELIM\n- Recurrent disease -ELIM predicts resistance\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- KELIM directly addresses your trial's focus on platinum response\n- KELIM validation in recurrent disease would strengthen your trial's biomarker analysis\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "Platinum resistance/sensitivity",
        "patient_population": "Recurrent ovarian cancer patients",
        "data_availability": "Phase 2 - may have preliminary outcomes",
        "kelim_relevance": [
          "Platinum-based therapy - perfect for KELIM",
          "Recurrent disease -ELIM predicts resistance"
        ]
      },
      "targeted_value_props": [
        "KELIM directly addresses your trial's focus on platinum response",
        "KELIM validation in recurrent disease would strengthen your trial's biomarker analysis",
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117720"
    },
    {
      "pi_name": "Laurent Brard, MD, PhD",
      "institution": "Southern Illinois University",
      "nct_id": "NCT02109367",
      "trial_details": {
        "title": "Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "41041279",
        "38492533",
        "37153054"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Laurent Brard,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass\" (NCTNCT02109367) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117732"
    },
    {
      "pi_name": "Thomas Woo, M.Sc.",
      "institution": "Quest PharmaTech Inc.",
      "nct_id": "NCT01616303",
      "trial_details": {
        "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Carboplatin",
          "Paclitaxel",
          "oregovomab"
        ]
      },
      "publications": [
        "33477405",
        "24303006",
        "21658270"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Thomas Woo,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer\" (NCTNCT01616303) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "Phase 2 - may have preliminary outcomes",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117743"
    },
    {
      "pi_name": "Sudha Sundar",
      "institution": "University of Birmingham/Sandwell and West Birmingham NHS Trust",
      "nct_id": "NCT06129968",
      "trial_details": {
        "title": "Transforming Ovarian Cancer Diagnostic Pathways",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "41321325",
        "41228382",
        "41194592"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Sudha,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"Transforming Ovarian Cancer Diagnostic Pathways\" (NCTNCT06129968) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117753"
    },
    {
      "pi_name": "Elise C Kohn, M.D.",
      "institution": "National Cancer Institute (NCI)",
      "nct_id": "NCT00086567",
      "trial_details": {
        "title": "Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "40192715",
        "39496422",
        "39361946"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Developing predictive biomarkers\n\nDear Dr. Elise C Kohn,\n\nI hope this email finds you well. I am reaching out because your research on Developing predictive biomarkers aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers\" (NCTNCT00086567) focuses on Developing predictive biomarkers. KELIM (CA-125 elimination rate) directly supports this goal by:\n- KELIM validation strengthens the biomarker evidence base\n- Your data contributes to establishing KELIM as a standard biomarker\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Developing predictive biomarkers"
      ],
      "how_we_help": [
        "KELIM validation strengthens the biomarker evidence base",
        "Your data contributes to establishing KELIM as a standard biomarker"
      ],
      "enhancement_date": "2025-12-30T02:42:01.117763"
    },
    {
      "pi_name": "Guillaume DUCARME, PH",
      "institution": "CHD Vend\u00e9e",
      "nct_id": "NCT02326064",
      "trial_details": {},
      "publications": [
        "31699959",
        "30917847",
        "22657746"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Guillaume DUCARME,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"\" (NCTNCT02326064) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117774"
    },
    {
      "pi_name": "Lucy Gilbert, MD,MSc,FRCOG",
      "institution": "McGill University",
      "nct_id": "NCT02296307",
      "trial_details": {
        "title": "DOvEE - Diagnosing Ovarian & Endometrial Cancer Early",
        "phase": [],
        "interventions": [
          "Blood test: CA-125 biomarker",
          "Second Test: Transvaginal Ultrasound",
          "Follow-up phone call"
        ]
      },
      "publications": [
        "41079774",
        "40700855",
        "40568887"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Aligned with Your Research on Advancing ovarian cancer treatment\n\nDear Dr. Lucy Gilbert,\n\nI hope this email finds you well. I am reaching out because your research on Advancing ovarian cancer treatment aligns perfectly with our KELIM biomarker validation study.\n\n**Why This Collaboration Makes Sense:**\n\nYour trial \"DOvEE - Diagnosing Ovarian & Endometrial Cancer Early\" (NCTNCT02296307) focuses on Advancing ovarian cancer treatment. KELIM (CA-125 elimination rate) directly supports this goal by:\n\n\n**What Makes Your Trial Ideal:**\n\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient) during first 100 days\n- Platinum-free interval (PFI) outcomes or progression dates\n- 50-100 patients minimum\n\n**What You Get:**\n- Co-authorship on vadation publication\n- Access to validated KELIM biomarker for your research\n- Enhanced biomarker analysis for your trial\n- Contribution to establishing KELIM as a standard tool\n\n**Why This Helps Your Research:**\n- Your expertise in ovarian cancer biomarkers makes you an ideal collaborator\n\nWe would be happy to discuss:\n- How KELIM can enhance your trial's biomarker analysis\n- Data sharing agreements and IRB considerations\n- Co-authorship and collaboration details\n- Any questions you may have\n\nThank you for your consideration. I look forward to discussing how we can advance ovarian cancer treatment together.\n\nBest regards,\n[Your Name]\n[Your Affiliation]\n[Your Contact Information]\n",
      "insights": {
        "trial_focus": "",
        "patient_population": "",
        "data_availability": "",
        "kelim_relevance": []
      },
      "targeted_value_props": [
        "Your expertise in ovarian cancer biomarkers makes you an ideal collaborator"
      ],
      "what_they_do": [
        "Advancing ovarian cancer treatment"
      ],
      "how_we_help": [],
      "enhancement_date": "2025-12-30T02:42:01.117862"
    }
  ],
  "date": "2025-12-30T02:42:01.118329"
}